Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR
Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Marcelo C. Pasquini(Cleveland Clinic), Mehdi Hamadani(Medical College of Wisconsin), Stephen Robinson(Intel (United States)), Harry C. Schouten, Hervé Finel, Jeanette Carreras(Medical College of Wisconsin), Ariane Boumedil(European Society for Blood and Marrow Transplantation), Timothy S. Fenske(Medical College of Wisconsin), Peter Dreger(Heidelberg University), Sonali M. Smith(University of Chicago), Mei‐Jie Zhang(Medical College of Wisconsin), Silvia Montoto(Queen Mary University of London)
Cited by 71
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
|New England Journal of Medicine|2018|1.1k